Needham & Company LLC reissued their hold rating on shares of Stryker Corp. (NYSE:SYK) in a report issued on Sunday.

“Analysts Conflictied on These Healthcare Names: Stryker (NYSE: SYK), Athersys (NASDAQ: ATHX) and Bio-Path Holdings (NASDAQ: BPTH) | Analyst Ratings

window._wpemojiSettings = {“baseUrl”:”https:\/\/s.w.org\/images\/core\/emoji\/72×72\/”,”ext”:”.png”,”source”:{“concatemoji”:”http:\/\/www.analystratings.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=4.5.4″}};
!function(a,b,c){function d(a){var c,d,e,f=b.createElement(“canvas”),g=f.getContext&&f.getContext(“2d”),h=String.fromCharCode;if(!g||!g.fillText)return!1;switch(g.textBaseline=”top”,g.font=”600 32px Arial”,a){case”flag”:return g.fillText(h(55356,56806,55356,56826),0,0),f.toDataURL().length>3e3;case”diversity”:return g.fillText(h(55356,57221),0,0),c=g.getImageData(16,16,1,1).data,d=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],g.fillText(h(55356,57221,55356,57343),0,0),c=g.getImageData(16,16,1,1).data,e=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],d!==e;case”simple”:return g.fillText(h(55357,56835),0,0),0!==g.getImageData(16,16,1,1).data[0];case”unicode8″:return g.fillText(h(55356,57135),0,0),0!==g.getImageData(16,16,1,1).data[0]}return!1}function e(a){var c=b.createElement(“script”);c.src=a,c.type=”text/javascript”,b.getElementsByTagName(“head”)[0].appendChild(c)}var f,g,h,i;for(i=Array(“simple”,”flag”,”unicode8″,”diversity”),c.supports={everything:!0,everythingExceptFlag:!0},h=0;h

var sampling_active = 0;
var sampling_rate = 100;
var do_request = false;

if ( !sampling_active ) {
do_request = true;
} else {
var num = Math.floor(Math.random() * sampling_rate) + 1;
do_request = ( 1 === num );
}

if ( do_request ) {

/* Create XMLHttpRequest object and set variables */
var xhr = ( window.XMLHttpRequest )
? new XMLHttpRequest()
: new ActiveXObject( “Microsoft.XMLHTTP” ),
url = ‘https://www.analystratings.com/wp-admin/admin-ajax.php’,
params = ‘action=update_views_ajax&token=b4868bde84&wpp_id=459998’;
/* Set request method and target URL */
xhr.open( “POST”, url, true );
/* Set request header */
xhr.setRequestHeader( “Content-type”, “application/x-www-form-urlencoded” );
/* Hook into onreadystatechange */
xhr.onreadystatechange = function() {
if ( 4 === xhr.readyState && 200 === xhr.status ) {
if ( window.console && window.console.log ) {
window.console.log( xhr.responseText );
}
}
};
/* Send request */
xhr.send( params );

}

(function(i,s,o,g,r,a,m){i[‘GoogleAnalyticsObject’]=r;i[r]=i[r]||function(){
(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
})(window,document,’script’,’//www.google-analytics.com/analytics.js’,’ga’);
ga(‘create’, ‘UA-55014446-1’, ‘auto’);
ga(‘send’, ‘pageview’);

window.$ = jQuery;

–>

Stock Market
Best Performing Analysts
Sectors

Basic Materials
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities

Most Popular
Contact Us

Home » Analysts Conflictied on These Healthcare Names: Stryker (NYSE: SYK), Athersys (NASDAQ: ATHX) and Bio-Path Holdings (NASDAQ: BPTH),” the firm’s analyst wrote.

A number of other analysts have also recently commented on the company. BMO Capital Markets raised Stryker Corp. from an underperform rating to a market perform rating and set a $125.00 price target on the stock in a research report on Tuesday, November 1st. They noted that the move was a valuation call. Zacks Investment Research raised Stryker Corp. from a sell rating to a hold rating and set a $129.00 price target on the stock in a research report on Monday, October 31st. Canaccord Genuity set a $127.00 price target on Stryker Corp. and gave the stock a buy rating in a research report on Sunday, October 30th. Oppenheimer Holdings Inc. set a $122.00 price target on Stryker Corp. and gave the stock a hold rating in a research report on Sunday, October 30th. Finally, SunTrust Banks Inc. assumed coverage on Stryker Corp. in a research report on Thursday, October 13th. They issued a buy rating and a $140.00 price target on the stock. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and twelve have given a buy rating to the stock. Stryker Corp. currently has an average rating of Hold and a consensus price target of $122.86.

Analyst Recommendations for Stryker Corp. (NYSE:SYK)

Shares of Stryker Corp. (NYSE:SYK) opened at 110.36 on Friday. Stryker Corp. has a 12 month low of $86.68 and a 12 month high of $123.55. The stock has a market capitalization of $41.32 billion, a P/E ratio of 25.12 and a beta of 0.86. The company’s 50 day moving average price is $115.24 and its 200-day moving average price is $114.92.

Stryker Corp. (NYSE:SYK) last posted its quarterly earnings data on Thursday, October 27th. The medical technology company reported $1.39 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.37 by $0.02. Stryker Corp. had a return on equity of 23.61% and a net margin of 15.24%. The business had revenue of $2.83 billion for the quarter, compared to analysts’ expectations of $2.81 billion. During the same period in the previous year, the firm posted $1.25 EPS. The business’s revenue was up 17.1% on a year-over-year basis. Equities analysts predict that Stryker Corp. will post $5.78 earnings per share for the current year.

In other Stryker Corp. news, Chairman Kevin Lobo sold 26,306 shares of the stock in a transaction dated Thursday, November 3rd. The shares were sold at an average price of $115.74, for a total transaction of $3,044,656.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 12,000 shares of the stock in a transaction dated Thursday, October 27th. The shares were sold at an average price of $110.18, for a total transaction of $1,322,160.00. Following the transaction, the director now directly owns 193,142 shares of the company’s stock, valued at approximately $21,280,385.56. The disclosure for this sale can be found here. 7.80% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Blue Chip Partners Inc. increased its position in Stryker Corp. by 0.3% in the second quarter. Blue Chip Partners Inc. now owns 1,757 shares of the medical technology company’s stock valued at $211,000 after buying an additional 6 shares during the period. Washington Trust Bank increased its position in Stryker Corp. by 0.5% in the second quarter. Washington Trust Bank now owns 3,040 shares of the medical technology company’s stock valued at $364,000 after buying an additional 15 shares during the period. Wetherby Asset Management Inc. increased its position in Stryker Corp. by 0.3% in the second quarter. Wetherby Asset Management Inc. now owns 6,242 shares of the medical technology company’s stock valued at $748,000 after buying an additional 18 shares during the period. Douglas Lane & Associates LLC increased its position in Stryker Corp. by 0.7% in the second quarter. Douglas Lane & Associates LLC now owns 2,945 shares of the medical technology company’s stock valued at $353,000 after buying an additional 20 shares during the period. Finally, Wade G W & Inc. increased its position in Stryker Corp. by 1.0% in the third quarter. Wade G W & Inc. now owns 2,230 shares of the medical technology company’s stock valued at $260,000 after buying an additional 22 shares during the period. 75.29% of the stock is owned by institutional investors and hedge funds.

Stryker Corp. Company Profile

Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.

5 Day Chart for NYSE:SYK

Receive News & Stock Ratings for Stryker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corp. and related stocks with our FREE daily email newsletter.